46. Malignant rheumatoid arthritis Clinical trials / Disease details

Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

8 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100050865	2020-07-18	2021-09-05	Observation on the efficacy of Tripterygium wilfordii polyglycosides tablets combined with Adamumab in the treatment of rheumatoid arthritis	A multicenter, prospective, observational study to evaluate the efficacy and safety of Tripterygium wilfordii polyglycosides combined with Adamumab in the treatment of rheumatoid arthritis	rheumatoid arthritis	1:Tripterygium wilfordii polyglycoside tablets + Adamu monoclonal antibody;2:Methotrexate tablets + Adamu monoclonal antibody ;	The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine	NULL	Recruiting	18	80	Both	1:30;2:30;	Phase 4	China
2	NCT04136262 (ClinicalTrials.gov)	September 1, 2019	21/10/2019	Tripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid Arthritis	Tripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid Arthritis: a Randomized Controlled Trial	Rheumatoid Arthritis	Drug: Tripterygium wilfordii Hook F (TwHF);Drug: Methotrexate;Other: Dummy Tripterygium wilfordii Hook F (TwHF)	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	NULL	Recruiting	N/A	N/A	Female	300	Phase 2/Phase 3	China
3	NCT03589833 (ClinicalTrials.gov)	July 2018	5/7/2018	Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA	Effectiveness and Safety of Tumor Necrosis Factor Receptor Fusion Protein(Yisaipu) Combined With Tripterygium Wilfordii for Active Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Tripterygium Wilfordii;Drug: Methotrexate;Drug: Yisaipu	Peking Union Medical College Hospital	NULL	Unknown status	18 Years	65 Years	All	504	Phase 2	China
4	NCT03337815 (ClinicalTrials.gov)	October 28, 2017	22/10/2017	A Specification Clinical Application Research of Tripterygium Wilfordii Treating Rheumatoid Arthritis	A 24-Week, Multicenter ,Double Blind, Randomized Study to Determine the Effects and Security of Tripterygium Wilfordii Treating Rheumatoid Arthritis and Establish A Prediction Model	Rheumatoid Arthritis	Drug: Treatment of MTX and TwHF placebo;Drug: Treatment of TwHF and MTX placebo	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	NULL	Recruiting	45 Years	70 Years	All	264	Phase 2/Phase 3	China
5	NCT01613079 (ClinicalTrials.gov)	May 2012	4/6/2012	Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis	Evaluation of Oral T2 (Chloroform/Methanol Extract of Tripterygium Wilfordii Hook F) in the Treatment of RA Patients With Clinical Efficacy and Safety.	Arthritis, Rheumatoid	Drug: Tripterygium wilfordii Hook F;Drug: Methotrexate	Peking Union Medical College Hospital	NULL	Completed	18 Years	65 Years	Both	201	Phase 2/Phase 3	China
6	NCT02818361 (ClinicalTrials.gov)	April 2012	15/6/2016	Topical Tripterygium Wilfordii Gel for Moderate Activity Rheumatoid Arthritis	Topical Tripterygium Wilfordii Gel for Treatment in Patients With Moderate Activity Rheumatoid Arthritis	Arthritis, Rheumatoid	Drug: Topical tripterygium gel;Drug: Placebo gel	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	NULL	Completed	18 Years	65 Years	All	70	N/A	China
7	NCT01961505 (ClinicalTrials.gov)	October 2011	23/9/2013	Topical Compound Tripterygium Wilfordii Hook F for Patients With Active Rheumatoid Arthritis	A Randomized Controlled Study to Determine the Effects and Safety of Topical Compound Tripterygium Wilfordii Hook F in Patients With Active Rheumatoid Arthritis.	Active Rheumatoid Arthritis	Drug: Topical compound tripterygium;Drug: Placebo	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	NULL	Completed	18 Years	65 Years	All	70	N/A	NULL
8	NCT00062465 (ClinicalTrials.gov)	June 2003	5/6/2003	Treating Rheumatoid Arthritis With Tripterygium Wilfordi Hook F or Sulfasalazine	A 24-Week, Double Blind, Randomized Study to Determine the Effects of 24 Weeks of Dosing With Tripterygium Wilfordii Hook F (TwHF) or Sulfasalazine, in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: TwHF	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Completed	N/A	N/A	Both	157	Phase 2	United States